Morepen Labs Bags Rs 825 Crore Global CDMO Deal
New Delhi: Morepen Laboratories Limited has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate worth approximately Rs 825 crore (USD 91 million) from a leading global pharmaceutical major, marking one of the largest single CDMO contracts in the company's history.
The Gurugram-based company informed stock exchanges on February 23, 2026, that supplies under the mandate are expected to commence within the next four to five months. The execution of the contract is scheduled through the first quarter of the following financial year, subject to customary operational and regulatory processes.
The deal represents a significant milestone as the company scales its global manufacturing footprint and strengthens its presence in the high-growth CDMO segment. Built on over four decades of active pharmaceutical ingredient (API) manufacturing expertise and regulatory credibility, Morepen’s CDMO platform enables structured, multi-year supply collaborations with global pharmaceutical innovators.
The mandate reflects the company’s expanding capabilities in regulated markets, backed by internationally accredited facilities approved by the USFDA, WHO-GMP, and EU authorities. With integrated development-to-commercial manufacturing capabilities, the company stated it is positioned to support complex scale-ups and long-duration supply frameworks. It is also evaluating capacity enhancement and technology investments aligned with its growing CDMO opportunity pipeline.
Commenting on the development, Sushil Suri, Chairman and Managing Director, said the mandate underscores the confidence global customers place in the company’s quality systems, regulatory track record, and execution capabilities. He noted that sustained strengthening of infrastructure and compliance depth over the years has enabled participation in larger, long-duration global programs.
Kushal Suri, President – International Growth (API), added that the engagement validates the company’s ability to qualify, execute, and deliver under regulated-market expectations, and positions it to convert similar opportunities into larger multi-year global programs.
According to the company, global pharmaceutical companies are increasingly consolidating supplier networks and partnering with compliant, scalable, and reliable manufacturing platforms to ensure long-term supply continuity.
